SYNACTIX PHARMACEUTICALS, INC.

Biotech · Defunct

An oral Aurora B kinase inhibitor small molecule for cancer treatment, specifically targeting acute myeloid leukemia

Grants
$640K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Pre-IND Study of Pz-1, a dual pan-RET/VEGFR2 inhibitor for the Treatment of RET-driven Disease$299,975
Federal grantDepartment of Health and Human Services · Phase I · Synactix Pharmaceuticals I-Corps Application$40,000
Federal grantDepartment of Health and Human Services · Phase I · Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML$299,975
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1597Novear Therapeutics LLC——
1598AVANT IMMUNOTHERAPEUTICS, INC.——
1599Reveal Pharmaceuticals, Inc.——
1600SYNACTIX PHARMACEUTICALS, INC.——
1601AllRock Bio——
1602TURTLETREE LABS INC.——
1603Maxwell Biosciences, Inc.—$11M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.